Skip to main content
. 2021 Jan 22;7(4):eabe7174. doi: 10.1126/sciadv.abe7174

Fig. 1. Schematic illustration of the mode of action of NV-ZIF.

Fig. 1

Targeted delivery of NV, a PD-1 antibody, to activate T cells in the slightly acidic tumor environment.